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Abstract
Background: Children with cow’s milk allergy (CMA) need a cow’s milk protein (CMP) free diet to prevent allergic
reactions. For this, reliable allergy-information on the label of food products is essential to avoid products
containing the allergen. On the other hand, both overzealous labeling and misdiagnosis that result in unnecessary
elimination diets, can lead to potentially hazardous health situations. Our objective was to evaluate if excluding
CMA by double-blind placebo-controlled food challenge (DBPCFC) prevents unnecessary elimination diets in the
long term. Secondly, to determine the minimum eliciting dose (MED) for an acute allergic reaction to CMP in
DBPCFC positive children.
Methods: All children with suspected CMA under our care (Oct’05 - Jun’09) were prospectively enrolled in a
DBPCFC. Placebo and verum feedings were administered on two randomly assigned separate days. The MED was
determined by noting the ‘lowest observed adverse effect level’ (LOAEL) in DBPCFC-positive children. Based on the
outcomes of the DBPCFC a dietary advice was given. Parents were contacted by phone several months later about
the diet of their child.
Results: 116 children were available for analysis. In 76 children CMA was rejected. In 60 of them CMP was successfully
reintroduced, in 2 the parents refused introduction, in another 3 the parents stopped reintroduction. In 9 children CMA
symptoms reappeared. In 40 children CMA was confirmed. Infants aged ≤ 12 months in our study group have a higher
cumulative distribution of MED than older children.
Conclusions: Excluding CMA by DBPCFC successfully stopped unnecessary elimination diets in the long term in most
children. The MEDs form potential useful information for offering dietary advice to patients and their caretakers.
Keywords: Cow’s milk allergy, Cow’s milk protein, Double-blind placebo-controlled provocation, Milk hypersensitivity,
Minimum eliciting dose
Background
The symptoms and signs of cow’s milk protein allergy
(CMA) are diverse, non-specific and also characteristic
of many other childhood diseases. Therefore, it is difficult
to correctly identify an adverse reaction to cow’s milk
protein (CMP) [1-4]. Children with CMA need a CMP-
free diet to prevent allergic reactions. For this, reliable
allergy-information on the label of food products is es-
sential to avoid products containing the allergen. On the
other hand, both overzealous labeling and misdiagnosis
that result in unnecessary elimination diets, can lead to
potentially hazardous health situations [2,5-7].
The real prevalence of CMA is only approximately 2-3%
in young children, although between 5 and 15% of infants
show symptoms suggestive of CMA [8-11]. Allergic
reactions to CMP can be IgE-mediated with an acute
(within 45 minutes) appearance of symptoms, or non-IgE-
mediated, with an intermediate (within several hours) or
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late (after 24–72 hours) appearance of symptoms [5,12].
Parentally perceived adverse reactions to milk are very
common and are the cause of milk-free diets in a substan-
tial number of patients [2,4,7,13-16]. They can cause nutri-
tional inadequacy, growth retardation, eating disorders and
psychosocial problems [4,6,7,17]. Excluding CMA in those
children who do not have it using a double-blind placebo-
controlled food challenge (DBPCFC), the golden standard
for the diagnosis of CMA, is important to prevent adverse
effects associated with an unnecessary elimination diet.
The DBPCFC outcome should also take into account
delayed reactions to food. Ignoring these could lead to un-
just rejection of the diagnosis of CMA by the physician or
persisting conviction in the parents that these late reactions
are a reaction to CMP.
In children who do have DBPCFC-proven CMA, a
CMP-free diet should be prescribed, irrespective of the
underlying immunological mechanism. Reliable allergy-
information on the label of food products supports
parents to realize this, especially for processed food
products because these may (intentionally or uninten-
tionally) contain CMP. To prevent unnecessary label-
ing of products that contain only trace amounts of
CMP to which CMA-patients do not react, knowledge of
the minimum eliciting dose (MED) of CMP is required.
The MED is defined as the minimal amount of allergen
at which an allergic reaction occurs. The MED can be
used to quantify the effects of specific amounts of aller-
gens in products, leading to accurate risk assessment and
clinically relevant product labeling. This is especially im-
portant for children with an acute IgE mediated allergic
reaction to cow’s milk, since these reactions are poten-
tially life-threatening. MED data in the youngest age
group are hardly available in the literature, whereas these
form the largest number of CMA patients.
The primary goal of our study was to evaluate if ex-
cluding CMA by a DBPCFC that includes assessment of
late reactions prevents unnecessary elimination diets in
the long term. Our secondary goal was to determine the
MEDs for CMP in children with an acute reaction to
CMP (within 2 hours after ingestion), to aid in clinically
relevant labeling of food products.
Patients and methods
Between October 2005 and June 2009, all children with
suspected CMA under our regional hospital care who
had been using a cow’s milk free diet for at least 4 weeks
were prospectively enrolled in a DBPCFC if informed
consent was given. Concomitant diseases e.g. atopic
dermatitis were no exclusion criterion. Also, no selection
was made based on the severity of CMA. At enrollment,
symptoms and signs that had led to the suspicion of
CMA were obtained from the parents and medical files.
Because it is important to prevent unnecessary and to
prescribe necessary elimination diets irrespective of the
underlying immunological mechanism, and because a
positive specific IgE does not prove CMA, the Dutch na-
tional protocol for the diagnosis of CMA does not advise
specific IgE or skin prick test in the diagnostic evalu-
ation of suspected CMA. Therefore, these were not per-
formed. This study was approved by the medical ethical
committee of the Jeroen Bosch Hospital.
The DBPCFC protocol (Table 1) was performed in
our pediatric day care ward on two separate days
with at least 1 week in between using placebo feed-
ing A and verum feeding B on randomly assigned
days. For placebo feeding A the child’s own commer-
cially available hydrolyzed infant formula was used
with which the child was symptom free. This formula
consisted of either Nutramigen (Mead Johnson,
Woerden, the Netherlands), Nutrilon Pepti (Nutricia,
Zoetermeer, the Netherlands) or Neocate (Nutricia,
Zoetermeer, the Netherlands). Feeding B contained a
quantity of cow's milk protein equal to regular infant
feedings (1.8 gram per 100 ml); it consisted of the
hydrolyzed infant formula used for feeding A and
Protifar (Nutricia, Zoetermeer, the Netherlands) in a
proportion of 11:3 [18]. Placebo and verum feedings
were equal in taste, color and smell. The feedings were
packed in identical blinded bottles. The randomization
code was packed in sealed, non-transparent envelopes
that remained closed until at least one week after the
second test day when the reactions had been assessed.
The parents, nursing staff, doctors and investigators
were unaware of the administered formula’s nature.
Acute reactions (within 2 hours after the test) were im-
mediately checked by the physician. Parents noted
reactions (within 72 hours after the test) in a home
diary. At home, patients continued their CMP free diet
until their visit to the outpatient clinic at least one
week after the second test day. There, the test was
interpreted according to the DBPCFC protocol and a
dietary advice was given (Table 1). Parents were con-
tacted by phone several months later about the symp-
toms and diet of their child.
Statistical analysis was performed using SPSS 19.0.
Two-sided chi-square tests with continuity correction
were performed for every single presenting symptom.
P-values <0,05 were considered significant.
For determination of the MED, only children with a
positive DBPCFC with symptoms within 2 hours after
ingestion of CMP were analyzed. The highest dose of
CMP at which no symptoms occur (‘no observed ad-
verse effect level’; NOAEL) and the dose of the first re-
action (‘lowest observed adverse effect level’; LOAEL)
were determined. Individual NOAELs and LOAELs
were used to fit a cumulative distribution using the
LIFEREG procedure of the SAS system (version 9.1)
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and applying interval censoring of the data (explained
in Taylor et al., 2009) [19-21]. Interval censoring is used
when the exact dose that provokes a reaction in an in-
dividual is not known, but is known to fall into a par-
ticular interval. Using a cumulative distribution makes
direct comparison of the distribution of MEDs in
populations of variable size possible. The result is a cu-
mulative distribution of the MEDs in which the prob-
ability (between 0 and 100%) of the allergic response is
presented that occurs at a certain dose (amount of pro-
tein intake) less than or equal to this certain dose. For
comparison, data from the literature [5,22-24] were fit-
ted using the same method. In determining the individ-
ual MED, we used the discrete dose at which the
symptoms occur instead of the cumulative dose for sev-
eral reasons. The interval time between the steps of the
protocol is 20 minutes. However, when there is a sub-
jective or mild objective symptom, the next dose is
awaited until the symptoms have disappeared. There-
after, the previous dose is repeated before the next dose
is given. This makes the contribution of previous doses
to the development of symptoms unclear. Secondly, in
a risk assessment a worst case scenario is preferred.
Therefore, we assume the discrete dosage is the elicit-
ing dose for the individual patient.
Results
Patients
One-hundred-and-twenty-four patients were eligible, of
which 51 (41%) were girls. Age at DBPCFC varied from
Table 1 The DBPCFC study algorithm
Part 1 The test (performed on two separate days with a 1 week
interval)
- No feedings from midnight onwards
- Admittance to pediatric day care ward at 8 AM.
- Physical examination by physician
- DBPCFC schedule
Step Time
(in minutes)
Amount
(in ml)
Amount
(in mg CMP)
1 0 1 18
2 20 10 180
3 40 20 360
4 60 30 540
5 80 40 720
6 100 60 1080
7 120 90 1620
- Physical examination by physician in case of suspected reaction;
if confirmed the test is stopped
- Physical examination by physician 20 minutes after last dose
- Clinical observation continued until 1 hour after last dose
- Parents are instructed about home symptoms’ diary
Part 2 Interpretation of test results
- Visit at outpatient department at least one week after
completing DBPCFC with assessment of reactions
- Envelope with randomization code is opened
- Diagnosis CMA is confirmed if symptoms appeared during or
within 72 hours after verum feeding and not during or within
72 hours after placebo feeding. These symptoms have to be
either identical to the presenting symptoms or severe
objective symptoms.
Part 3 Dietary advice
- CMA: continue a diet free of CMP and repeat challenge in future
- No CMA: reintroduction of CMP over a 4 week period
Week Amount of CMP in feeding
1 ¼ cow’s milk containing feeding and ¾ hydrolyzed
formula
2 1/3 cow’s milk containing feeding and 2/3 hydrolyzed
formula
3 2/3 cows milk containing feeding and 1/3 hydrolyzed
formula
4 Exclusively cow’s milk containing feeding
Part 4 Long term follow up
- Interview by telephone about the child’s diet and symptoms
CMA, cow’s milk allergy; CMP, cow’s milk protein; DBPCFC, double-blinded
placebo- controlled food challenge.
Table 2 Presenting symptoms of all 124 eligible children
Symptom Number of patients (%)
Gastrointestinal tract
Vomiting 30 (24.2%)
Diarrhea 17 (13.7%)
Constipation 14 (11.3%)
Colic 24 (19.4%)
Bloody stool 17 (13.7%)
Abdominal pain 3 (2.4%)
Feeding problems 15 (12.1%)†
Respiratory tract
Dyspnea and wheezing 13 (10.5%)
Skin manifestations
Eczema 50 (40.3%)
Swelling 5 (4.0%)‡
Urticaria 3 (2.4%)
Erythematous exanthema 10 (8.1%)
Other
Excessive crying 59 (47.6%)
Positive family history 8 (6.5%)*
† Feeding problems were significantly more often present in the DBPCFC-
negative group (p=0.046).
‡ Swelling was significantly more often present in the DBPCFC-positive
group (p=0.023).
*In these 8 children the positive family history was one of the reasons for
performing the double-blind placebo-controlled food challenge. In total 65
children (52.4%) had a positive family history.
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2.5 months to 134 months (median 7.5 months). In 6
children the DBPCFC was not completed. In 5 of these
children, this was because they refused to drink the test
feedings. In one child the DBPCFC failed because of an
intercurrent infection. One child didn’t meet the inclu-
sion criterion of a CMP free diet for at least 4 weeks.
Therefore 116 children are available for further analysis.
Presenting symptoms
The presenting symptoms of the 124 eligible children
are listed in Table 2. Feeding problems were significantly
more often present in the DBPCFC-negative group
(p=0.046). Swelling was significantly more often present
in the DBPCFC-positive group (p=0.023), all four tested
patients with this presenting symptom had a positive
DBPCFC. The remaining presenting symptoms were not
significantly more often present in the DBPCFC-positive
or in the DBPCFC-negative children. The number of
presenting symptoms was also not significantly different
between the two groups. None of the patients presented
with an anaphylactic reaction.
Results of DBPCFC
Test results were interpreted according to the type and
timing of reactions (Table 3). In 76 children (66%) the
diagnosis of CMA was rejected (n=56 <1 year, n=20
1–3 years of age). In 38 (33%) the diagnosis was
confirmed (n= 27 <1 year, n= 7 1–3 years, n=4 >3 years
of age). Details about the MED and the type of reactions
at this dose are listed in Table 4. In 12 of these 38 chil-
dren (32%) an acute reaction occurred. In 15 of the 38
children (39%) there was a late reaction, and 11 (29%)
showed both an acute and a late reaction. In two children
an objective acute reaction to placebo feeding alone was
observed. The first of these two children (nr 74) devel-
oped an acute itching rash on the arms and face after the
first dose (18 mg), the second child (nr 118) developed
itching eyes and swelling of the mouth after the second
dose (180 mg). Although reactions to placebo have been
described in the literature, these children were inter-
preted as having CMA with accidentally exchanged pla-
cebo and verum feedings by their treating physician and
parents were advised to continue the CMP free diet.
They were excluded from further analysis of the MED. In
17 of the 76 children (22%) with a negative DBPCFC a
reaction occurred on placebo feeding alone (an acute re-
action in 1 child (vomiting), a late reaction in 14 and an
acute plus late reaction in 2).
Reintroduction of cow’s milk
Follow-up was performed by contacting parents by tele-
phone several months after the reintroduction. When
we were unable to reach parents by telephone, informa-
tion was gathered from the medical file. Information on
Table 3 The 116 successful tests
Reaction Children Conclusion Reintroduction
Number Percentage
No reaction to both feedings 55 47 No CMA A: 49
B: 2
C: 2
D: 1
E: 1
Comparable reaction after both feedings 4 3 No CMA A: 2
C: 1
D: 1
Acute reaction after placebo feeding (vomiting) 1 1 No CMA A: 1
Late reaction after placebo feeding 14 12 No CMA A: 8
D: 5
E: 1
Acute and late reaction after placebo feeding 2 2 No CMA D: 2
Objective acute reaction after placebo feeding alone 2 2 CMA; interpreted as accidentally exchanged placebo
and verum feedings by treating physician
Acute reaction after verum feeding 12 10 CMA
Late reaction after verum feeding 15 13 CMA
Acute and late reaction after verum feeding 11 10 CMA
CMA, cow’s milk allergy; A, successful reintroduction; B, parents refused to reintroduce cow’s milk; C, reintroduction stopped without medical advice; D,
reintroduction stopped with medical advice; E: no information available on reintroduction.
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reintroduction was available in 74 of the 76 DBPCFC
negative children (Table 3) with a mean follow-up of
12 months (range 1–31 months). In 60 of the 74 chil-
dren (81%) in whom the diagnosis of CMA was
rejected, cow’s milk was successfully reintroduced per-
manently. In 9 children (12%) symptoms reappeared
upon reintroduction of cow’s milk. Symptoms included
crying, worsening of eczema and diarrhea. The symp-
toms disappeared with re-elimination of cow’s milk
from the diet. Therefore, they were interpreted by the
treating physician as an allergic reaction to cow’s milk,
with a false negative DBPCFC, probably due to reac-
tions that only become apparent upon prolonged feed-
ing with high doses of CMP. In 7 of these 9 children
a reaction to placebo feeding alone had been observed
that was equal to the presenting symptoms. These
reactions consisted of colic, diarrhea, vomiting, ec-
zema, erythema, itching, crying and sleeping problems.
In one there was a comparable reaction to both feed-
ings (diarrhea, colic), the other child had no reaction
to either of the feedings. In 5 of the 74 children (7%)
parents refused or stopped reintroduction.
MED
23 children showed a positive DBPCFC with an acute
reaction within 2 hours after ingestion of CMP. This
excludes the two children with an acute reaction to pla-
cebo feeding who were interpreted as having CMA by
their treating physician. Information on NOAEL and
LOAEL was unavailable for 2 children due to incom-
plete medical files. Therefore, 21 children were available
for determining the MEDs. Figure 1 shows the number
of allergic responders at each MED in this population
of 21 children (the Jeroen Bosch Hospital population;
JBH population). For comparison between age groups,
the total population was divided in two subgroups
according to age (0–12 months, n=14; >12 months,
n=7). To enable comparison of the two populations the
individual MED are presented as a cumulative probabil-
ity distribution (Figure 2). Data from the literature
derived from the study populations of Flinterman et al.
(n=11) [5], Baehler et al. (n=16) [22], Caminiti et al.
(n=13) [23] and Patriarca et al. (n=8) [24] are repre-
sented in the same figure. Detailed information on the
populations represented in Figure 2 is shown in Table 5.
Figure 2 shows that the highest cumulative distribution
of MEDs was in our study subgroup of children aged 0 –
12 months. The cumulative MED distribution of our
population of children aged > 12 months group is com-
parable to the patient groups described in the literature.
Discussion
An accurate diagnosis of CMA is important to reduce
the number of children on inappropriate diets. Many
Table 4 LOAEL symptoms of the DBPCFC-positive children
Patient Age (months) Sex Amount of CMP (mg) Symptoms
Acute reactions
29 7,5 F ? ery
30 134 M ? os, nau
35 115 M 18 sw
63 4 M 18 ery
108 42,5 F 18 os, vom, sw
34 10 M 180 ery
90 26 F 360 ery, ur
42 14,5 M 540 ur
93 3 M 540 col
6 3,5 M 720 ery
107 7 M 720 cry, vom
14 5,5 M 1080 ery, ur
85 5 M 1080 dia
104 119 M 1080 ap, nau
47 11 M 1620 ery, vom, dysp, whe
54 8,5 F 1620 vom
59 7,5 M 1620 ery
66 24 F 1620 ery
87 7 F 1620 ec
95 6 M 1620 cry, dia
114 11 F 1620 dia, ery, cry, agi
121 17 M 1620 ery, ur
123 4 F 1620 agi, fp
Late reactions
9 7,5 F 1620 dia, cry
19 12,5 M 1620 sp, ery
21 6 M 1620 ec, con
27 5,5 M 1620 dysp
32 5,5 M 1620 ec, cry
37 2,5 F 1620 agi
39 5 F 1620 cry
62 13 F 1620 col, cry, con
65 7 F 1620 con
73 7 M 1620 agi, cry, dia
76 15,5 F 1620 cry, sp
79 7,5 F 1620 vom, cry
86 5 F 1620 dia
103 4 M 1620 agi
111 4,5 F 1620 con
DBPCFC, double-blinded placebo-controlled food challenge; LOAEL, lowest
observed adverse effect level; agi, agitation; ap, abdominal pain; col, colic; con,
constipation; cry, crying; dia, diarrhea; dysp, dyspnea; ec, worsening eczema; ery,
erythema; fp, feeding problems; itch, itching; nau, nausea; os, oropharyngeal
symptoms; sw, swelling; ur, urticaria; vom, vomiting; whe, wheezing; sp, sleeping
problems. Amounts of 18, 180, 360, 540, 720, 1080 and 1620 mg CMP correspond
with 1, 10, 20, 30, 40, 60 and 90 ml test feeding respectively.
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studies using DBPCFC with CMP to evaluate the inci-
dence of CMA have been retrospective [3], and/or did
not include late reactions [25]. None included long-
term follow up to assess if parents continued to fol-
low the medical advice based on the DBPCFC. In our
study DBPCFC led to the long-term use of an appro-
priate diet based on the presence or absence of CMA
in 100 (88%) of 114 children tested (intention-to-treat
analysis; information on long term diet was unavail-
able in 2 children).
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Figure 1 Responders with an acute reaction at each dose. The number of cow’s milk allergic children with an acute reaction of the Jeroen
Bosch Hospital at each dose of cow’s milk (expressed as CMP). Amounts of 18, 180, 360, 540, 720, 1080 and 1620 mg CMP correspond with 1, 10,
20, 30, 40, 60 and 90 ml test feeding respectively. JBH_children is the patient selection of DBPCFC-positive children older than 12 months.
JBH_infants consists of DBPCFC-positive children aged 0 – 12 months. See Table 4 for details on each individual.
Figure 2 Cumulative MEDs for an acute allergic reaction to cow's milk protein in the JBH population compared to various CMA
studies. Cumulative probability distribution based on individual MEDs for cow’s milk (expressed as CMP) for cow’s milk allergic children of the
Jeroen Bosch Hospital and for populations from the literature [5,22-24]. 100 mg CMP corresponds with 5,6 ml of our test feeding. Two
distributions were compiled for the JBH population. JBH_children is the patient selection of DBPCFC-positive children older than 12 months.
JBH_infants consists of DBPCFC-positive children aged 0 – 12 months. See also Table 5. CMA, cow’s milk allergy; CMP, cow’s milk protein; JBH,
Jeroen Bosch Hospital; MED, minimum eliciting dose. ▲ JBH_children; ■ JBH_infants; □ Flinterman et al. (2006); ▬ Baehler et al. (1996); ♦
Caminiti et al. (2009); ○ Patriarca et al. (2002).
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Besides acute reactions, we also studied late reactions
which typically develop within 24 to 72 hours after
ingesting CMP. When late reactions are described in the
literature, they form a substantial part of the positive test
results, ranging from 20% to 60% [22,26]. When only
acute reactions are included, as in the study by Schade
et al. [25], a much lower incidence of CMA is found
than mentioned in the literature. In our study popula-
tion, 37.5% of the 40 children with CMA developed a
late reaction alone. A limitation of our study is, that the
only information we have about late reactions comes
from the parents; it is hardly feasible to hospitalise chil-
dren for a total of 6 days to perform a DBPCFC. How-
ever, only symptoms that were identical to the original
presenting symptoms that occurred after verum feeding
but not after placebo feeding were interpreted as a posi-
tive DBPCFC. Systematically ignoring late reactions in
DBPCFC would lead to an unjust rejection of the diag-
nosis of non-IgE-mediated CMA.
The presenting symptom of swelling was significantly
more often present in the DBPCFC positive group. None
of these children had a negative test. This is not surpris-
ing, since swelling is usually an immediate IgE-mediated
hypersensitivity reaction. In these cases, the diagnosis is
more easily made on clinical presentation. However, pre-
senting symptoms of urticaria, erythema, vomiting and
respiratory tract symptoms, which can also be inter-
preted as IgE-mediated reactions when occurring as an
immediate reaction, were not significantly different be-
tween the two groups. This emphasizes the need for a
DBPCFC for diagnosing or excluding CMA.
Reactions to placebo are described in the literature.
Vlieg-Boerstra et al. found them in 12.9% of all their
DBPCFC tests and in 5/43 (11,6%) of their cow’s milk
DBPCFC’s [27]. Hospers et al. describe a reaction to pla-
cebo feeding in 24% of their tests [3]. We also found
them in 17 children (22%). The precise cause for this is
not known. We cannot fully exclude the possibility that
placebo and verum feedings were accidentally exchanged
in some of the cases with a reaction to placebo feeding
alone, because 7 DBPCFC negative children in our study
group who had developed a reaction after placebo feed-
ing alone were later interpreted as having CMA based
on recurrence of symptoms after the reintroduction of
CMP. However, a reaction to placebo feeding alone oc-
curred in 9 additional DBPCFC negative children in
whom CMP was successfully reintroduced.
A possible explanation for a false negative result is
the possibility that the threshold to respond is higher
than the dose achieved during the challenge, i.e. larger
quantities of allergen are needed to produce a reaction.
Sicherer et al. [28] studied the quantity of food that
elicited a reaction during DBPCFC in children with
atopic dermatitis. Of 117 children (median age 5 years
9 months) with positive reactions to CMP, in 12% the re-
action occurred after the final test dose of 2 to 2,5 grams
or during open challenge. These children received a total
of 8 to 10 grams of CMP. In our study the final dose con-
sisted of 1,6 grams and a total of 4,5 grams of CMP was
ingested during the test. So, it could be that some chil-
dren in our study did not receive a high enough dose to
produce a reaction.
Unfortunately, the data represented by Sicherer
et al. is not detailed enough for us to determine a cu-
mulative distribution of the MEDs of their study
group for comparison with our study group. Recent
research has explored the importance of having ad-
equate MED-data available for population risk assess-
ment purposes which makes optimal use of all
available information, including the dose distribution
of MEDs within the allergic population [29,30]. How-
ever studies that are developed to determine MEDs
often only describe the lowest MED within the popu-
lation encountered, whereas a distribution of MEDs
within that population is not established [31]. Flinter-
man et al. [5], Baehler et al. [22], Caminiti et al. [23]
and Patriarca et al. [24] however, do represent data in
their studies describing allergic reactions to CMP
which can be used for determining the cumulative
distribution of MEDs in their population.
Table 5 Information on the populations represented in Figure 1
Study population Hospital Patient selection Number of
patients
Mean age in years
(range)
JBH_infants Regional hospital All children with suspected CMA aged 0 – 12 months. 14 0,6 (0,3 – 0,9)
JBH_children Regional hospital All children with suspected CMA aged > 12 months 7 4,2 (1,2 – 9,9)
Flinterman et al.[5] Tertiary referral centre Children sensitized to CMP and with AEDS as reason for
prolonged CM elimination.
11 4,1 (1,8 – 10,3)
Baehler et al.[22] Tertiary referral centre Children with suspected CMA. All children with chronic
atopic dermatitis are excluded.
16 3,1 (0,7 – 8,8)
Caminiti et al.[23] Tertiary referral centre Children with severe IgE-mediated CMA 13 8 (5 – 10)
Patriarca et al.[24] Tertiary referral centre Children with CMA from the outpatient clinic offered an
oral desensitization.
8 9 (5 – 15)
AEDS, atopic eczema dermatitis syndrome; CM, cow’s milk; CMA, cow’s milk allergy; CMP, cow’s milk protein; JBH, Jeroen Bosch Hospital.
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It is striking that our subgroup of infants aged
≤ 12 months has a higher cumulative MED distribution
than the children aged > 12 months. This suggests that
infants have a higher MED than older children, and
therefore will react only to higher amounts of CMP.
This is supported by the studies from the literature used
for comparison. The cumulative MED distributions
based on these studies are also lower than the cumulative
MED distribution of our infant group. As can be seen in
Table 5, the age distribution of the children described in
the literature is comparable to our subgroup of children
aged > 12 months. However, there are some important
differences between our study and the studies in the lit-
erature, which makes comparison difficult. At first, we
performed our study in a regional hospital. All the stud-
ies from the literature were performed in a tertiary refer-
ral centre, which can lead to a different patient selection.
Patients visiting a tertiary referral centre may have a
more severe CMA, and therefore a lower MED. Sec-
ondly, our study is the only study that included all chil-
dren with suspected CMA, without selection based on
the presence or absence of atopic dermatitis. Also no se-
lection was made based on the severity of CMA.
The population of Flinterman et al. [5] is most similar
to our subgroup of children considering the age distribu-
tion. However, they included only children with atopic
dermatitis. The children described by Baehler et al. [22]
are somewhat younger, however they excluded all chil-
dren with co-existing atopic dermatitis. The children in
the study groups of Caminiti et al. [23] and Patriarca
et al. [24] are not only older than our population, but
also consist of a selected patient group. These two stud-
ies were performed to investigate the effect of oral
desensitization, and children with a ‘severe’ CMA were
selected. It is not surprising that these children have a
lower MED distribution. Therefore, our study seems
more representative for the general population of chil-
dren with CMA compared to the other studies men-
tioned above. Our study is the only one that included
enough infants to allow a separate distribution for chil-
dren aged ≤ 12 months. With the possible exception of
the study by Baehler et al., in which the age distribution
is not clearly described, none of the studies included
children under the age of 12 months.
A recent paper by Brand et al. [32] states that the indi-
vidual MED remains fairly constant over time, however
we found no other studies in the literature to confirm
this statement. They also state that 75% of infants with
CMA are cow’s milk tolerant by the age of 1 year. 90%
are cow’s milk tolerant by the age of 4 years. A study by
Host et al. [33] in 2002 investigated the natural history
of CMA. They found a recovery of CMA in 56% of
patients at 1 year, 77% at 2 years, 87% at 3 years, 92% at
5 and 10 years and 97% at 15 years of age. In our study
group, older children have a lower cumulative distribu-
tion of MED than the infants aged 0 – 12 months. An
interesting discussion point is whether this means that
the infants with a higher MED will become cow’s milk
tolerant and infants with a lower MED will remain aller-
gic to cow’s milk. Another hypothesis is that there is
some kind of selection bias. Infants in general consume
more milk than older children. Therefore both infants
with a relatively high MED and a low MED might seek
medical attention in contrast to older children who
would just start consuming less cow’s milk products and
don’t seek medical advice unless they have a lower MED.
Further follow-up studies are needed to confirm these
hypotheses and to investigate whether the individual
MED remains constant over time. At this point, the cu-
mulative distribution of the MED in a population can
only be used for population risk assessment purposes.
Conclusion
By excluding CMA by DBPCFC most parents are con-
vinced the symptoms of their child are not caused by
CMP and are willing to permanently stop an unneces-
sary elimination diet. This study shows that it is import-
ant to include late reactions to CMP in the DBPCFC
test. By ignoring these late reactions the diagnosis of
CMA would have been rejected unjustly in 37,5% of the
children in our study. Also, by ignoring late symptoms
parents could remain convinced that these symptoms
are attributable to CMP and therefore would unneces-
sarily continue an elimination diet.
When CMA is proven, the DBPCFC can be used to de-
termine the MED and the cumulative MED distribution.
The MEDs form potential useful information for offering
dietary advice to patients and their caretakers and for
population risk assessment purposes. Our study shows that
older children have a lower cumulative MED distribution
than the infants in our study group, and thus react to smal-
ler amounts of CMP. Further studies are needed to investi-
gate if the individual MED can also be used to predict the
chance of an infant becoming cow’s milk tolerant.
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